Cited by 1,008T-cell and B-cell ImmunologyCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record; 41 of the 44 references it cites were found in a registry or an index.

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

Open access

Sutmuller, Roger P.M., van Duivenvoorde, Leonie M., van Elsas, Andrea, Schumacher, Ton N.M., Wildenberg, Manon E., Allison, James P., Toes, Rene E.M., Offringa, Rienk, Melief, Cornelis J.M.·2001·The Journal of Experimental Medicine

DOI 10.1084/jem.194.6.823PMC PMC2195955

Open this paper in CoChat — free account

Abstract

Therapeutic efficacy of a tumor cell–based vaccine against experimental B16 melanoma requires the disruption of either of two immunoregulatory mechanisms that control autoreactive T cell responses: the cytotoxic T lymphocyte–associated antigen (CTLA)-4 pathway or the CD25+ regulatory T (Treg) cells. Combination of CTLA-4 blockade and depletion of CD25+ Treg cells results in maximal tumor rejection. Efficacy of the antitumor therapy correlates with the extent of autoimmune skin depigmentation as well as with the frequency of tyrosinase-related protein 2180–188–specific CTLs detected in the periphery. Furthermore, tumor rejection is dependent on the CD8+ T cell subset. Our data demonstrate that the CTL response against melanoma antigens is an important component of the therapeutic antitumor response and that the reactivity of these CTLs can be augmented through interference with immunoregulatory mechanisms. The synergism in the effects of CTLA-4 blockade and depletion of CD25+ Treg cells indicates that CD25+ Treg cells and CTLA-4 signaling represent two alternative pathways for suppression of autoreactive T cell immunity. Simultaneous intervention with both regulatory mechanisms is therefore a promising concept for the induction of therapeutic antitumor immunity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1084/jem.194.6.823

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells
Park, J., Adoro, S., Guinter, T. I., Erman, B., Alag, A., Catálfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 1×
“H-2K b tetramers were produced as described previously (20, 21) and stored frozen in Tris-buffered saline/16% glycerol/0.”
Method
CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production
Thornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,637
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 2×
“Anderson Cancer Center, Houston, TX), GM-CSF‐producing B16 cell lines BL6/GM-E, BL6/GM18 (18), B16/B7.1 (18), 9H10 ( 19 ), and PC61 (American Type Culture Collection) were cultured in Iscove’s IMDM (BioWhittaker) supplemented with 1 U/ml penicillin, 1 � g/ml streptomycin, 2 � M L -glutamine, 20 � M � -mercaptoethanol…”
MethodSelf-citation
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
B7/CD28 Costimulation Is Essential for the Homeostasis of the CD4+CD25+ Immunoregulatory T Cells that Control Autoimmune Diabetes
Salomon, B. L., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A. H., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,058
Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state.
Takahashi, T., Kuniyasu, Y., Toda, M., Sakaguchi, N., Itoh, M., Iwata, M., Shimizu, J., & Sakaguchi, S. (1998) · International Immunology · doi:10.1093/intimm/10.12.1969 · Cited by 1,566

Flagged first, then by citations

Show all 44 references

3 of the 44 references couldn’t be matched to a known paper.

Sorted by citations

Items 501–600 of 1,000

The role of T-regulatory cells in pregnancy and cancer
Jacek, R. W. (2007) · Frontiers in bioscience · doi:10.2741/2841 · Cited by 42
Development of Antibodies and Chimeric Molecules for Cancer Immunotherapy
Waldmann, T. A., & Morris, J. C. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90003-0 · Cited by 42
CD4+CD25+ regulatory T cells in human hematopoietic cell transplantation
Zorn, E. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.11.008 · Cited by 42
T regulatory cells, the evolution of targeted immunotherapy
Nizar, S. A., Meyer, B., Galustian, C., Kumar, D., & Dalgleish, A. G. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.02.001 · Cited by 41
Regulatory T Cells
Golovina, T. N., & Vonderheide, R. H. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eb336d · Cited by 41
Differential Ability of Surface and Endosomal TLRs To Induce CD8 T Cell Responses In Vivo
Mandraju, R., Murray, S. E., Forman, J., & Pasare, C. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302244 · Cited by 41
Role of Immune Escape Mechanisms in Hodgkin's Lymphoma Development and Progression: A Whole New World with Therapeutic Implications
de la Cruz‐Merino, L., Lejeune, M., Fernández, E. N., Henao, F., López, A. G., Illescas-Vacas, A., Provencio, M., Callau, C., & Álvaro, T. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/756353 · Cited by 42
Proportion of CD4 CD25 Regulatory T Cell is Increased in the Patients with Ovarian Carcinoma
Li, X., Ye, D.-F., Xie, X., Chen, H., & Lü, W. (2005) · Cancer Investigation · doi:10.1081/cnv-67142 · Cited by 41
Association of T-cell regulatory gene polymorphisms with oral squamous cell carcinoma
Kämmerer, P. W., Toyoshima, T., Schöder, F., Kämmerer, P., Kuhr, K., Brieger, J., & Al‐Nawas, B. (2010) · Oral Oncology · doi:10.1016/j.oraloncology.2010.03.025 · Cited by 40
Tumor cells prevent mouse dendritic cell maturation induced by TLR ligands
Idoyaga, J., Moreno, J. G., & Bonifaz, L. C. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0275-y · Cited by 42
Altered Immunity Accompanies Disease Progression in a Mouse Model of Prostate Dysplasia
Tien, A. H., Xu, L., & Helgason, C. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3271 · Cited by 40
Identification of vaccine targets & design of vaccine against SARS-CoV-2 coronavirus using computational and deep learning-based approaches
Abbasi, B. A., Saraf, D., Sharma, T., Sinha, R., Singh, S., Sood, S., Gupta, P., Gupta, A., Mishra, K., Kumari, P., et al. (2022) · PeerJ · doi:10.7717/peerj.13380 · Cited by 39
Self-assembling peptides as immunomodulatory biomaterials
Hernández, A., Hartgerink, J. D., & Young, S. W. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1139782 · Cited by 39
The importance of correctly timing cancer immunotherapy
Nejad, E. B., Welters, M. J. P., Arens, R., & van der Burg, S. H. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1256388 · Cited by 39
The Immune System's Contribution to the Clinical Efficacy of EGFR Antagonist Treatment
Macdonald, F., & Zaiss, D. M. W. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00575 · Cited by 40
Tumor immune escape mechanisms: impact of the neuroendocrine system
Lang, K., Entschladen, F., Weidt, C., & Zaenker, K. S. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0126-x · Cited by 39
Immunosuppression in Melanoma Immunotherapy: Potential Opportunities for Intervention
Lizee, G. A., Radvanyi, L. G., Overwijk, W. W., & Hwu, P. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2537 · Cited by 39
Antibodies designed as effective cancer vaccines
Metheringham, R. L., Pudney, V. A., Gunn, B., Towey, M., Spendlove, I., & Durrant, L. G. (2009) · mAbs · doi:10.4161/mabs.1.1.7492 · Cited by 39
Dual Role of Heat Shock Proteins (HSPs) in Anti-Tumor Immunity
Multhoff, G., Pockley, A. G., Streffer, C., & Gaipl, U. S. (2012) · Current Molecular Medicine · doi:10.2174/156652412803306666 · Cited by 38
Homeostasis of peripheral FoxP3+ CD4+ regulatory T cells in patients with early and late stage breast cancer
Rech, A. J., Mick, R., Kaplan, D. E., Chang, K., Domchek, S. M., & Vonderheide, R. H. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0780-x · Cited by 38
T Cell‐Tumor Interaction Directs the Development of Immunotherapies in Head and Neck Cancer
Albers, A. E., Strauss, L., Liao, T., Hoffmann, T. K., & Kaufmann, A. M. (2010) · Journal of Immunology Research · doi:10.1155/2010/236378 · Cited by 38
Mechanisms of tumor evasion from the immune response
Rodrı́guez, P. C., Zea, A. H., & Ochoa, A. C. (2003) · Cancer chemotherapy and biological response modifiers · doi:10.1016/s0921-4410(03)21018-8 · Cited by 38
Immune regulation by CD4+CD25+ regulatory T cells: implications for transplantation tolerance
Taams, L. S., Vukmanovic‐Stejic, M., Salmon, M., & Akbar, A. N. (2003) · Transplant Immunology · doi:10.1016/s0966-3274(03)00047-9 · Cited by 38
Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy
Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37
Reprogramming the tumor microenvironment with biotechnology
Kim, M., Lee, N. K., Wang, C. J., Lim, J., Byun, M. J., Kim, T. P., Park, W., Park, D.-H., Kim, S.-N., & Park, C. G. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00343-4 · Cited by 37
Modulating T regulatory cells in cancer: how close are we?
Banerjee, A., Vasanthakumar, A., & Grigoriadis, G. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2013.12 · Cited by 38
Expression of costimulatory and inhibitory receptors in FoxP3+ regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches
Toker, A., & Ohashi, P. S. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.05.001 · Cited by 38
Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences
Chung, C. K., Silva, C. G. D., Kralisch, D., Chan, A. B., OSSENDORP, F. A., & Cruz, L. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.011 · Cited by 38
A Comparison and Critical Analysis of Preclinical Anticancer Vaccination Strategies
Kochenderfer, J. N., & Gress, R. E. (2007) · Experimental Biology and Medicine · doi:10.3181/0702-mr-42 · Cited by 37
Regulatory T Cells, Leptin and Angiogenesis
Pucino, V., Rosa, V. D., Procaccini, C., & Matarese, G. (2013) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000353557 · Cited by 37
Current Experience With CTLA4-blocking Monoclonal Antibodies for the Treatment of Solid Tumors
Agarwala, S. S., & Ribas, A. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181dcd260 · Cited by 36
LncRNA MIAT Services as a Noninvasive Biomarker for Diagnosis and Correlated with Immune Infiltrates in Breast Cancer
Ye, T., Feng, J. Y., Cui, M., Yang, J., Wan, X., Xie, D., & Liu, J. (2021) · International Journal of Women s Health · doi:10.2147/ijwh.s312714 · Cited by 36
Advancements in immune tolerance
Pan, P., Ozao, J. J., Zhou, Z., & Chen, S. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.025 · Cited by 38
Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival
Dobrzanski, M. J., Rewers‐Felkins, K., Quinlin, I. S., Samad, K. A., Phillips, C. A., Robinson, W., Dobrzanski, D. J., & Wright, S. E. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.08.007 · Cited by 37
Tumor cells secreting IL-13 but not IL-13R 2 fusion protein have reduced tumorigenicity in vivo
Ma, H.-L. (2004) · International Immunology · doi:10.1093/intimm/dxh105 · Cited by 39
CD4+ T Cells Are Able to Promote Tumor Growth through Inhibition of Tumor-Specific CD8+ T-Cell Responses in Tumor-Bearing Hosts
den Boer, A. T., van Mierlo, G. J. D., Fransen, M. F., Melief, C. J. M., Offringa, R., & Toes, R. E. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3344 · Cited by 36
Self-citation
Large-Scale Depletion of CD25+ Regulatory T Cells from Patient Leukapheresis Samples
Powell, D. J., Parker, L. L., & Rosenberg, S. A. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000170363.22585.5a · Cited by 36
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine
Zamarin, D., & Jazaeri, A. A. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.12.030 · Cited by 35
Expression Profiling of Murine Double-Negative Regulatory T Cells Suggest Mechanisms for Prolonged Cardiac Allograft Survival
Lee, B. P.-L., Mansfield, E. S., Hsieh, S., Hernandez‐Boussard, T., Chen, W., Thomson, C. W., Ford, M. S., Bosinger, S. E., Der, S., Zhang, Z., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4535 · Cited by 35
An enteric pathogen Salmonella enterica serovar Typhimurium suppresses tumor growth by downregulating CD44high and CD4T regulatory (Treg) cell expression in mice: the critical role of lipopolysaccharide and Braun lipoprotein in modulating tumor growth
Liu, T., & Chopra, A. K. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.58 · Cited by 35
Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies.
Murillo, O., Arina, A., Tirapu, I., Alfaro, C., Mazzolini, G. D., Palencia, B., de Cerio, A. L.-D., Prìeto, J., Bendandi, M., & Melero, I. (2003) · PubMed · Cited by 35
Complementary role of CD4+CD25+ regulatory T cells and TGF-β in oral tolerance
Chung, Y., Lee, S., Kim, D., & Kang, C. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.1004599 · Cited by 35
Ultraviolet radiation and tumor immunity
de Gruijl, F. R. (2002) · Methods · doi:10.1016/s1046-2023(02)00200-1 · Cited by 35
Checkpoint blockade in combination with cancer vaccines
Morse, M. A., & Lyerly, H. K. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.057 · Cited by 34
Enhancing the efficacy of cancer vaccines in urologic oncology: new directions
Kusmartsev, S. A., & Vieweg, J. (2009) · Nature Reviews Urology · doi:10.1038/nrurol.2009.177 · Cited by 34
Cytotoxic T-lymphocyte antigen 4 gene polymorphisms and susceptibility to chronic hepatitis B
Alizadeh, A. H. M. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i4.630 · Cited by 34
Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects
Facciabene, A., Aurisicchio, L., Elia, L., Palombo, F., Mennuni, C., Ciliberto, G., & Monica, N. L. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.10.060 · Cited by 34
Immunology of Vaccine Adjuvants
Ribeiro, C. M. S., & Schijns, V. E. C. J. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-585-9_1 · Cited by 34
Successful elimination of large established tumors and avoidance of antigen‐loss variants by aggressive adoptive T cell immunotherapy
Matsui, K., O’Mara, L. A., & Allen, P. M. (2003) · International Immunology · doi:10.1093/intimm/dxg078 · Cited by 34
The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses
Chakraborty, M., Schlom, J., & Hodge, J. W. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0291-6 · Cited by 33
Cytokine, Chemokine, and Co-Stimulatory Fusion Proteins for the Immunotherapy of Solid Tumors
Khawli, L. A., Hu, P., & Epstein, A. L. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_13 · Cited by 33
Downregulation of CD4+CD25+ regulatory T cells may underlie enhanced Th1 immunity caused by immunization with activated autologous T cells
Cao, Q., Wang, L. L., Du, F., Sheng, H., Zhang, Y., Wu, J., Shen, B., Shen, T.-W., Zhang, J., Li, D., et al. (2007) · Cell Research · doi:10.1038/cr.2007.46 · Cited by 33
Mechanisms of T Cell Tolerance and Suppression in Cancer Mediated by Tumor-Associated Antigens and Hormones
Adler, A. J. (2007) · Current Cancer Drug Targets · doi:10.2174/156800907780006931 · Cited by 33
Molecular Profiling of Melanoma and the Evolution of Patient-Specific Therapy
Gajewski, T. F. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.01.004 · Cited by 32
Ipilimumab augments antitumor activity of bispecific antibody-armed T cells
Yano, H., Thakur, A. B., Tomaszewski, E. N., Choi, M., Deol, A., & Lum, L. G. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-191 · Cited by 32
Induction of Tolerance by Adoptive Transfer of Treg Cells
Nagahama, K., Nishimura, E., & Sakaguchi, S. (2007) · Methods in molecular biology · doi:10.1007/978-1-59745-395-0_27 · Cited by 32
CXCR5/CXCL13 Interaction Is Important for Double-Negative Regulatory T Cell Homing to Cardiac Allografts
Lee, B. P.-L., Chen, W., Shi, H., Der, S. D., Förster, R., & Zhang, L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.9.5276 · Cited by 32
Combination B7-Fc Fusion Protein Treatment and Treg Cell Depletion Therapy
Liu, A., Hu, P., Khawli, L. A., & Epstein, A. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1411 · Cited by 32
CTLA-4 exon 1 +49 polymorphism alone and in a haplotype with −318 promoter polymorphism may confer susceptibility to chronic HBV infection in Chinese Han patients
Duan, S., Zhang, G., Han, Q., Zhu, L., Liu, Z., Chen, J., Lv, Y., Li, N., Wang, Y., Li, M., et al. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0660-7 · Cited by 32
Listeriolysin O Expressed in a Bacterial Vaccine Suppresses CD4+CD25high Regulatory T Cell Function In Vivo
Nitcheu-Tefit, J., Dai, M., Critchley-Thorne, R. J., Ramirez-Jimenez, F., Xu, M., Conchon, S., Ferry, N., Stauss, H. J., & Vassaux, G. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.3.1532 · Cited by 32
Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response
Scott, I. (2005) · Frontiers in bioscience · doi:10.2741/1575 · Cited by 32
Depletion of Foxp3+ Regulatory T Cells Promotes Profibrogenic Milieu of Cholestasis-Induced Liver Injury
Roh, Y. S., Park, S., Lim, C. W., & Kim, B. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3438-2 · Cited by 32
In Vivo Depletion of CD4+CD25+ Regulatory T Cells Enhances the Antigen-Specific Primary and Memory CTL Response Elicited by Mature mRNA-Electroporated Dendritic Cells
Meirvenne, S. V., Dullaers, M., Heirman, C., Straetman, L., Michiels, A., & Thielemans, K. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.02.029 · Cited by 32
Induction of regulatory T cell–resistant helper CD4+ T cells by bacterial vector
Nishikawa, H., Tsuji, T., Jäger, E., Briones, G., Ritter, G., Old, L. J., Galán, J. E., Shiku, H., & Gnjatic, S. (2007) · Blood · doi:10.1182/blood-2007-09-113761 · Cited by 32
Dendritic Cell-Based Tumor Vaccines and Antigen Presentation Attenuators
Evel-Kabler, K., & Chen, S. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.02.009 · Cited by 32
Mucosal Immunity and HIV-1 Infection: Applications for Mucosal AIDS Vaccine Development
Belyakov, I. M., & Ahlers, J. D. (2011) · Current topics in microbiology and immunology · doi:10.1007/82_2010_119 · Cited by 31
IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression
Ohmatsu, H., Humme, D., Gonzalez, J., Gulati, N., Möbs, M., Sterry, W., & Krueger, J. G. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1181237 · Cited by 32
A Novel CAR Expressing NK Cell Targeting CD25 With the Prospect of Overcoming Immune Escape Mechanism in Cancers
Dehbashi, M., Hojati, Z., Motovali-Bashi, M., Ganjalikhany, M. R., Cho, W. C. S., Shimosaka, A., Navabi, P., & Ganjalıkhani-Hakemi, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.649710 · Cited by 32
Beyond adjuvants: Immunomodulation strategies to enhance T cell immunity
Kamphorst, A. O., Araki, K., & Ahmed, R. (2015) · Vaccine · doi:10.1016/j.vaccine.2014.12.082 · Cited by 31
Tumor immunity via homeostatic T cell proliferation: mechanistic aspects and clinical perspectives
Baccalà, R., González‐Quintial, R., Dummer, W., & Theofilopoulos, A. N. (2005) · Springer Seminars in Immunopathology · doi:10.1007/s00281-004-0196-9 · Cited by 31
Regulatory T cells as adjuvant target for enhancing the viral disease vaccine efficacy
Bayry, J. (2013) · VirusDisease · doi:10.1007/s13337-013-0187-3 · Cited by 31
Anti–human CTLA-4 monoclonal antibody promotes T-cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies
May, K. F., Roychowdhury, S., Bhatt, D., Kocak, E., Bai, X., Liu, J.-Q., Ferketich, A. K., Martin, E. W., Caligiuri, M. A., Zheng, P., et al. (2004) · Blood · doi:10.1182/blood-2004-07-2561 · Cited by 31
Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects
Petrausch, U., Poehlein, C. H., Jensen, S. M., Twitty, C., Thompson, J., Assmann, I., Puri, S., LaCelle, M. G., Moudgil, T. L., Maston, L. D., et al. (2009) · Current Molecular Medicine · doi:10.2174/156652409788970670 · Cited by 31
Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial
Luke, J. J., Zha, Y., Matijevich, K., & Gajewski, T. F. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0140-2 · Cited by 31
Signal transducer and activator of transcription 6 (Stat6) and CD1: inhibitors of immunosurveillance against primary tumors and metastatic disease
Ostrand‐Rosenberg, S., Sinha, P., Clements, V. K., Dissanayake, S. I., Miller, S., Davis, C., & Danna, E. A. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0446-z · Cited by 31
Revival of the regulatory T cell: new targets for drug development
Sutmuller, R. P. M., Offringa, R., & Melief, C. J. M. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(03)03021-6 · Cited by 31
Self-citation
Chemoimmunotherapy Reduces the Progression of Multiple Myeloma in a Mouse Model
Sharabi, A., Laronne, A., Meshorer, A., & Haran‐Ghera, N. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0138 · Cited by 30
Immunotherapies: The Blockade of Inhibitory Signals
Wu, Y., Liang, J., Zhang, W., Tanaka, Y., & Sugiyama, H. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.5273 · Cited by 32
Bilateral murine tumor models for characterizing the response to immune checkpoint blockade
Zemek, R. M., Fear, V. S., Forbes, C., de Jong, E., Casey, T. H., Boon, L., Lassmann, T., Bosco, A., Millward, M., Nowak, A. K., et al. (2020) · Nature Protocols · doi:10.1038/s41596-020-0299-3 · Cited by 31
Role of CD4+CD25+FOXP3+TRegcells on tumor immunity
Hariyanto, A. D., Permata, T. B. M., & Gondhowiardjo, S. A. (2021) · Immunological Medicine · doi:10.1080/25785826.2021.1975228 · Cited by 31
Phase- and Stage-Related Proportions of T Cells Bearing the Transcription Factor FOXP3 Infiltrate Primary Melanoma
Panfilis, G. D., Campanini, N., Santini, M., Mori, G., Tognetti, E., Maestri, R., Lombardi, M., Froio, E., Ferrari, D., & Ricci, R. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701046 · Cited by 30
Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression
Larmonier, N., Cantrell, J., LaCasse, C. L., Li, G., Janikashvili, N., Situ, E., Sepassi, M., Andreansky, S. S., & Katsanis, E. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0907635 · Cited by 30
A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer
Riezebos‐Brilman, A., Walczak, M., Regts, J., Rots, M. G., Kamps, G., Dontje, B., Haisma, H. J., Wilschut, J., & Daemen, T. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303036 · Cited by 30
Regulatory T‐cells promote hepatitis B virus infection and hepatocellular carcinoma progression
Li, W., Han, J., & Wu, H. M. (2016) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2016.09.001 · Cited by 30
Regulatory T cells and the liver
Chang, K. (2005) · Hepatology · doi:10.1002/hep.20678 · Cited by 30
Regulatory T-Cells and Autoimmunity
Choileain, N. N., & Redmond, H. P. (2006) · Journal of Surgical Research · doi:10.1016/j.jss.2005.07.033 · Cited by 30
Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors
Davis-Marcisak, E. F., Fitzgerald, A. A., Kessler, M. D., Danilova, L., Jaffee, E. M., Zaidi, N., Weiner, L. M., & Fertig, E. J. (2021) · Genome Medicine · doi:10.1186/s13073-021-00944-5 · Cited by 29
Prevention of Allogeneic Cardiac Graft Rejection by Transfer of Ex Vivo Expanded Antigen-Specific Regulatory T-Cells
Takasato, F., Morita, R., Schichita, T., Sekiya, T., Morikawa, Y., Kuroda, T., Niimi, M., & Yoshimura, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087722 · Cited by 29
Immunotherapeutic Strategies for High-Risk Bladder Cancer
Sharma, P., Old, L. J., & Allison, J. P. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.12.004 · Cited by 29
Self-citation
Denileukin Diftitox (Ontak) as Maintenance Therapy for Peripheral T-Cell Lymphomas: Three Cases with Sustained Remission
Fuentes, A. C., Szwed, E., Spears, C. D., Thaper, S. K., Dang, L. H., & Dang, N. H. (2015) · Case Reports in Oncological Medicine · doi:10.1155/2015/123756 · Cited by 28
An Overview of the Immune Modulatory Properties of Long Non-Coding RNAs and Their Potential Use as Therapeutic Targets in Cancer
Martínez‐Castillo, M., Elsayed, A. M., Lopez‐Berestein, G., Amero, P., & Rodriguez‐Aguayo, C. (2023) · Non-Coding RNA · doi:10.3390/ncrna9060070 · Cited by 28
Regulatory T Cells: A New Frontier in Cancer Immunotherapy
Barnett, B. G., Rüter, J., Kryczek, I., Brumlik, M. J., Cheng, P. J., Daniel, B. J., Coukos, G., Zou, W., & Curiel, T. J. (2008) · Springer eBooks · doi:10.1007/978-0-387-68969-2_20 · Cited by 28
Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials
Park, H. J., & Neelapu, S. S. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07143.x · Cited by 28
Tumour infiltrating host cells and their significance for hyperthermia
Muthana, M., Multhoff, G., & Pockley, A. G. (2010) · International Journal of Hyperthermia · doi:10.3109/02656730903413375 · Cited by 28
Effective Cooperation of Monoclonal Antibody and Peptide Vaccine for the Treatment of Mouse Melanoma
Ly, L. V., Sluijter, M., van der Burg, S. H., Jager, M. J., & van Hall, T. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200135 · Cited by 28
DNA vaccination with T‐cell epitopes encoded within Ab molecules induces high‐avidity anti‐tumor CD8+ T cells
Pudney, V. A., Metheringham, R. L., Gunn, B., Spendlove, I., Ramage, J. M., & Durrant, L. G. (2009) · European Journal of Immunology · doi:10.1002/eji.200939857 · Cited by 28
Regulatory T Cells in Cancer
Piconese, S., & Colombo, M. P. (2007) · Springer eBooks · doi:10.1007/978-0-387-69118-3_4 · Cited by 28
Regulatory T cells: present facts and future hopes
Becker, C., Stoll, S., Bopp, T., Schmitt, E., & Jonuleit, H. (2006) · Medical Microbiology and Immunology · doi:10.1007/s00430-006-0017-y · Cited by 28
Highly clonal regulatory T-cell population in follicular lymphoma – inverse correlation with the diversity of CD8+T cells
Liu, X., Venkataraman, G., Lin, J., Kiyotani, K., Smith, S. M., Montoya, M., Nakamura, Y., & Kline, J. P. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.1002728 · Cited by 27
Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy
Alimohammadi, R., Alibeigi, R., Nikpoor, A. R., Chalbatani, G. M., Webster, T. J., Jaafari, M. R., & Jalali, S. A. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s260760 · Cited by 27

Authors: Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M.
Affiliations: Leiden University Medical Center (NL)
aDepartment of Immunohematology and Blood Transfusion, Tumor Immunology Lab, E3-Q, Leiden University Medical Center, 2300 RC Leiden, Netherlands
The Netherlands Cancer Institute (NL)
University of California, Berkeley (US)
ORCID: Schumacher, Ton N.M.
Wildenberg, Manon E.
Allison, James P.
Offringa, Rienk
Melief, Cornelis J.M.
Venue: The Journal of Experimental Medicine
Publisher: Rockefeller University Press
Published: 2001-09-17
Volume: 194
Issue: 6
Pages: 823-832
ISSN: 0022-1007 (ISSN-L)
1540-9538
DOI: 10.1084/jem.194.6.823
PMC: PMC2195955
OpenAlex: W2148911309
Cited by: 1,008
References: 44
Citations by year: 2026: 3 · 2025: 7 · 2024: 8 · 2023: 12 · 2022: 15 · 2021: 15 · 2020: 18 · 2019: 11 · 2018: 12 · 2017: 25 · 2016: 22 · 2015: 36 · 2014: 26 · 2013: 48 · 2012: 41
FWCI: 13.30
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: cc-by-nc-sa
Locations: The Journal of Experimental Medicine (publishedVersion)
PubMed Central (publishedVersion, cc-by-nc-sa)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CTLA-4 blockade, CD25+ regulatory T cells, Treg depletion, antitumor immunity, B16 melanoma, CD8+ T cells, tyrosinase-related protein 2, immune regulation, tumor rejection
MeSH terms: Abatacept, Animals, Antibodies, Monoclonal, Antigens, Differentiation, Antigens, Neoplasm, Female, Immunotherapy, Lymphocyte Depletion, Melanoma, Experimental, Mice, Inbred C57BL, Mice, Nude, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, Receptors, Interleukin-2, Biomarkers, CD4-Positive T-Lymphocytes, Antigens, CD, Immunoconjugates, Intramolecular Oxidoreductases, Mice, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks